sentiment_stocks
3 minutes ago
13% leans closer to 15% than 10%. Besides, the overall 5% survival rate includes IDH mutated (who generally live longer, and who there were very few of in our trial, and who are no longer considered GBM patients but astrocytoma grade 4), so my thinking is that the 5% survival rate at 5 years leans